I Rácz

ORCID: 0000-0001-9740-6995
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastrointestinal Bleeding Diagnosis and Treatment
  • Helicobacter pylori-related gastroenterology studies
  • Gastrointestinal disorders and treatments
  • Gastric Cancer Management and Outcomes
  • Drug Solubulity and Delivery Systems
  • Inflammatory Bowel Disease
  • Ecology and Vegetation Dynamics Studies
  • Microscopic Colitis
  • Analytical Chemistry and Chromatography
  • Gastroesophageal reflux and treatments
  • Eosinophilic Esophagitis
  • Orthoptera Research and Taxonomy
  • Colorectal Cancer Screening and Detection
  • Analytical Methods in Pharmaceuticals
  • Gastrointestinal Tumor Research and Treatment
  • Botany and Plant Ecology Studies
  • Inflammatory mediators and NSAID effects
  • Anesthesia and Sedative Agents
  • Esophageal and GI Pathology
  • Surfactants and Colloidal Systems
  • Syphilis Diagnosis and Treatment
  • Chemical Thermodynamics and Molecular Structure
  • Synthesis and Reactions of Organic Compounds
  • Gallbladder and Bile Duct Disorders
  • Advanced Drug Delivery Systems

Petz Aladár Megyei Oktató Kórház
2012-2023

Széchenyi István University
2012-2023

University of Debrecen
2007-2023

Hungarian National Museum
2021

Universitätsklinikum Knappschaftskrankenhaus Bochum
2012

Ruhr University Bochum
2012

Hospital General Universitario de Alicante Doctor Balmis
2012

Hungarian Natural History Museum
2011

Hungarian Academy of Sciences
2007

Semmelweis University
1995-2005

Overexpression of cyclooxygenase 2 (COX-2) has been associated with colorectal adenomatous polyps and cancer, prompting researchers to propose its inhibition as a chemopreventive intervention.The Prevention Colorectal Sporadic Adenomatous Polyps trial was randomized, placebo-controlled, double-blind study the COX-2 inhibitor celecoxib given daily in single 400-mg dose. At 107 centers 32 countries, we randomly assigned 1561 subjects who had adenomas removed before enrollment receive (933...

10.1056/nejmoa061652 article EN New England Journal of Medicine 2006-08-30

Suppressing acid secretion is thought to reduce the risk of ulcers associated with regular use nonsteroidal antiinflammatory drugs (NSAIDs), but best means accomplishing this uncertain.

10.1056/nejm199803123381104 article EN New England Journal of Medicine 1998-03-12

This Guideline is an official statement of the European Society Gastrointestinal Endoscopy (ESGE). It addresses diagnosis and management nonvariceal upper gastrointestinal hemorrhage (NVUGIH). <b>Main Recommendations</b> <b>MR1.</b> ESGE recommends immediate assessment hemodynamic status in patients who present with acute (UGIH), prompt intravascular volume replacement initially using crystalloid fluids if instability exists (strong recommendation, moderate quality evidence). <b>MR2.</b> a...

10.1055/s-0034-1393172 article EN Endoscopy 2015-09-29

The European Society of Gastrointestinal Endoscopy and United Gastroenterology present a short list key performance measures for lower gastrointestinal endoscopy. We recommend that endoscopy services across Europe adopt the following seven measurement evaluation in daily practice at center endoscopist level: <b>1</b> Rate adequate bowel preparation (minimum standard 90 %); <b>2</b> Cecal intubation rate <b>3</b> Adenoma detection 25 <b>4 </b>Appropriate polypectomy technique 80 <b>5</b>...

10.1055/s-0043-103411 article EN Endoscopy 2017-03-07

This Guideline is an official statement of the European Society Gastrointestinal Endoscopy (ESGE) and Gastroenterology Nurses Associates (ESGENA). It addresses administration propofol by non-anesthesiologists for gastrointestinal (GI) endoscopy. <b>Main Recommendations</b> <b>1</b> We recommend that type endoscopic procedure patient's American Anesthesiologists (ASA) physical status, age, body mass index, Mallampati's classification, risk factors obstructive sleep apnea (OSA) be assessed...

10.1055/s-0034-1393414 article EN Endoscopy 2015-11-12

To determine whether eradication of Helicobacter pylori relieves the symptoms functional dyspepsia.Multicentre randomised double blind placebo controlled trial.278 patients infected with H who had dyspepsia.Predominantly secondary care centres in Australia, New Zealand, and Europe.Patients to receive omeprazole 20 mg twice daily, amoxicillin 1000 clarithromycin 500 daily or for 7 days. Patients were followed up 12 months.Symptom status (assessed by diary cards) presence gastric biopsies...

10.1136/bmj.318.7187.833 article EN BMJ 1999-03-27

See also: Retraction of endorsement: European Society Gastrointestinal Endoscopy, Gastroenterology and Endoscopy Nurses Associates, the Anaesthesiology Guideline: Non-anesthesiologist administration propofol for GI endoscopyEndoscopy 2012; 44(03): 302-302DOI: 10.1055/s-0031-1291648 Reply to PelosiEndoscopy 10.1055/s-0031-1291649

10.1055/s-0030-1255728 article EN Endoscopy 2010-11-11

OBJECTIVES Low-dose aspirin is standard treatment for prevention of cardiovascular events in at-risk patients. However, long-term administration low-dose associated with a greater risk adverse events, including gastroduodenal ulcers. This study determined the efficacy esomeprazole reducing gastric and/or duodenal ulcers and dyspeptic symptoms patients receiving continuous, therapy. METHODS Patients aged ≥60 yr, without baseline ulcer at endoscopy, who were 75–325 mg once daily, randomized to...

10.1111/j.1572-0241.2008.01995.x article EN The American Journal of Gastroenterology 2008-07-11

The safety and efficacy of fontolizumab, a humanized anti-interferon gamma antibody, was investigated in patients with Crohn's disease (CD). Elevated gut mucosal levels interferon gamma, key cytokine involved the inflammatory process CD, are associated symptoms. A total 201 Disease Activity Index (CDAI) scores between 250 450 were randomized to receive an initial intravenous dose 1.0 or 4.0 mg/kg fontolizumab placebo, followed by up 3 subcutaneous doses 0.1 placebo every 4 weeks. Clinical...

10.1002/ibd.21038 article EN Inflammatory Bowel Diseases 2009-07-28

<h3>Objectives:</h3> To determine the therapeutic equivalence and safety of once daily (OD) versus three times (TID) dosing a total dose 3 g Salofalk (mesalazine) granules in patients with active ulcerative colitis. <h3>Design:</h3> A randomised, double-blind, double-dummy, parallel group, multicentre, international, phase III non-inferiority study. <h3>Setting:</h3> 54 centres 13 countries. <h3>Patients:</h3> 380 confirmed diagnosis established or first attack colitis (clinical activity...

10.1136/gut.2008.154302 article EN cc-by-nc Gut 2008-10-02

CCX282-B, also called vercirnon, is a specific, orally-administered chemokine receptor CCR9 antagonist that regulates migration and activation of inflammatory cells in the intestine. This randomized, placebo-controlled trial was conducted to evaluate safety efficacy CCX282-B 436 patients with Crohn's disease. Disease Activity Index (CDAI) scores were 250-450 C-reactive protein >7.5 mg/L at study entry. In addition stable concomitant medication (85% subjects), subjects received placebo or...

10.1371/journal.pone.0060094 article EN cc-by PLoS ONE 2013-03-20

10.1023/a:1022958003528 article EN Landscape Ecology 2003-01-01

Propofol sedation by non-anaesthesiologists is an upcoming regimen in several countries throughout Europe. Numerous studies have shown the efficacy and safety of this gastrointestinal endoscopy. Nevertheless, issue remains highly controversial. The aim evidence- consensus-based set guideline to provide with a comprehensive framework for propofol during digestive This results from collaborative effort representatives European Society Gastrointestinal Endoscopy (ESGE), Gastroenterology Nurses...

10.1097/eja.0b013e32834136bf article EN European Journal of Anaesthesiology 2010-11-11

Aliment Pharmacol Ther 2011; 33: 313–322 Summary Background Comparative data regarding different regimens of oral mesalazine (mesalamine) for maintaining remission in ulcerative colitis are limited. Aim To evaluate whether 3.0 g once-daily (OD) is superior to the standard treatment 0.5 three times daily (t.d.s.) and prove therapeutic equivalence OD vs. t.d.s. dosing total 1.5 maintenance patients with colitis. Methods A 1-year, multicentre, double-blind, double-dummy study was undertaken...

10.1111/j.1365-2036.2010.04537.x article EN Alimentary Pharmacology & Therapeutics 2010-12-08

OBJECTIVES: Subjects in the Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trial (PRESAP/NCT00141193/www.clinicaltrials.gov) were studied to determine efficacy and safety at a year 5 assessment. METHODS: In this randomized, placebo-controlled, double-blind trial, 1,561 subjects with diagnosed colorectal adenomas removed within 3 months study's initiation assessed after ∼3 years on celecoxib followed by 2 off. Studied 107 primary secondary care settings, stratified...

10.1038/ajg.2011.116 article EN The American Journal of Gastroenterology 2011-04-19

To evaluate the gastro-protective effect of capsaicin against ethanol- and indomethacin (IND)-induced gastric mucosal damage in healthy human subjects.The effects small doses (1-8 microg/mL, 100 mL) on acid secretion basal output (BAO) its electrolyte concentration, transmucosal potential difference (GTPD), (5 mL 300 mL/L i.g.) IND- (3x25 mg/d) induced were tested a randomized, prospective study 84 subjects. The possible role desensitization capsaicin-sensitive afferents was by repeated...

10.3748/wjg.v11.i33.5180 article EN PubMed 2005-09-07

Background and Aim:Adalimumab [ADA] was approved for the treatment of ulcerative colitis [UC] refractory to conventional therapy in 2012 Europe. Due observed discrepancies between clinical trials practice, data on outcome ADA are really needed from real life. The aim this study estimate short- long-term efficacy safety UC patients each Hungarian biological centre.

10.1093/ecco-jcc/jjv169 article EN Journal of Crohn s and Colitis 2015-09-20

YEOMANS, NEVILLE D.; TULASSAY, ZSOLT; JUHÁSZ, LÁSZLÓ; RÁCZ, ISTVÁN; HOWARD, JOHN M.; VAN RENSBURG, CHRISTOFFEL J.; SWANNELL, ANTHONY HAWKEY, CHRISTOPHER J. FOR THE ACID SUPPRESSION TRIAL: RANITIDINE VERSUS OMEPRAZOLE NSAID-ASSOCIATED ULCER TREATMENT (ASTRONAUT) STUDY GROUP Author Information

10.1097/00132586-199906000-00058 article EN Survey of Anesthesiology 1999-06-01

Previous studies have suggested an increasing use of complementary and alternative medicine (CAM) in patients with inflammatory bowel disease (IBD). Furthermore, a significant number IBD fail to comply treatment. The aim our study was evaluate the prevalence non-adherence CAM Hungarian IBD.A total 655 consecutive (CD: 344, age: 38.2 [SD 12.9]years; UC: 311, 44.9 [15.3]years) were interviewed during specialist visit by self-administered questionnaire including demographic disease-related data...

10.1016/j.crohns.2009.11.011 article EN Journal of Crohn s and Colitis 2009-12-18

Studies on allele length polymorphism designate several glacial refugia for Norway spruce (Picea abies) in the South Carpathian Mountains, but infer only limited expansion from these after last glaciation. To better understand genetic dynamics of a lineage, we compared ancient DNA 10,700 and 11,000-year-old pollen macrofossils retrieved Holocene lake sediment Retezat Mountains with extracted extant material same site. We used eight primer pairs that amplified short variable regions cpDNA. In...

10.1186/1471-2148-11-66 article EN cc-by BMC Evolutionary Biology 2011-03-10

The paper overviews the endemism hot-spots of European Orthoptera and reveals paleogeographic processes which have shaped recent faunal structures fauna. Descriptions seven centres (the southern Balkan Peninsula western Asia Minor; Dinaric Mountains; Alps; Ap- penines; Carpathian Mountains Basin; Iberian Peninsula; Caucasian Mountains) are given. Significance these areas is not only mirrored in richness endemic species but also postglacial expansion aims study were to summarize literature...

10.3409/azc.52b_1-2.189-211 article EN Acta Zoologica Cracoviensia - Series B Invertebrata 2009-06-30
Coming Soon ...